Abstract
Background and Aims The outbreak of Coronavirus Disease 2019 (COVID-19) may affect the disease status of patients with inflammatory bowel disease (IBD). This study aimed to assess the disease status of IBD patients in Hubei province by questionnaire online and guide to the self-management of IBD patients during this epidemic.
Methods A questionnaire was designed containing the Harvey-Bradshaw Index (HBI), the Partial Mayo Score (PMS), the short inflammatory bowel disease questionnaire (SIBDQ) and distributed to Hubei IBD patients online within one month of traffic control after the outbreak of COVID-19. This questionnaire also included some questions about patients’ self-report disease conditions and their epidemiological history of COVID-19.
Results A total of 102 eligible questionnaires were included in the analysis. No patient reported infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in our study. Our result showed that 69.64% of patients with ulcerative colitis (UC) and 80.44% of patients with Crohn’s disease (CD) were in remission. There was not a statistically significant difference in the proportion of the active disease stage between the two types of disease (p=0.103). The majority of patients (85.29%) had a good health-related quality of life (HRQoL) (SIBDQ≥50). The reduction in physical exercise is a risk factor for worsening in conditions (OR=17.593, 95%CI 2.035 to 152.097, p=0.009).
Conclusions The outbreak of COVID-19 might not have a significant impact on most Hubei IBD patients within one month after the traffic control. The patient’s disease condition could be assessed by our questionnaires. Doctors utilized the information and advised for IBD patients about self-management during the period of COVID-19.
- questionnaire
- inflammatory bowel disease
- Coronavirus Disease 2019
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Science Foundation of China (81470807 to FX, 81873556 to FX) and Wu Jieping Medical Foundation (320.6750.17397 to FX).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ contact details: Meiping Yu, Email: 904313468{at}qq.com, Zhenghao Ye, Email: xczgyzh{at}163.com, Yu Chen, Email: magicalmirrors{at}163.com, Tingting Qin, Email: qintingting77{at}163.com, Jiguang Kou, Email: kjg700917{at}aliyun.com, De’an Tian, Email: datian{at}tjh.tjmu.edu.cn, Fang Xiao, Email: xiaofang{at}tjh.tjmu.edu.cn
Data Availability
All data, models, and code generated or used during the study appear in the submitted article.The data used to support the findings of this study are available from the corresponding author upon request.
Abbreviations
- COVID-19
- Coronavirus Disease 2019
- IBD
- inflammatory bowel disease
- HBI
- Harvey-Bradshaw Index
- PMS
- Partial Mayo Score
- SIBDQ
- short inflammatory bowel disease questionnaire
- SARS-COV-2
- severe acute respiratory syndrome coronavirus 2
- UC
- ulcerative colitis
- CD
- Crohn’s disease
- HRQoL
- health-related quality of life
- OR
- odds ratio
- IQR
- interquartile range